(oral transmucosal fentanyl citrate)
Actiq® is indicated for the management of breakthrough pain in patients already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.1
Patients receiving maintenance opioid therapy are those who are taking at least 60mg of oral morphine daily, at least 25mcg of transdermal fentanyl per hour, at least 30mg of oxycodone daily, at least 8mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.1
One Actiq® lozenge contains 200mcg / 400mcg / 600mcg / 800mcg / 1200mcg / 1600mcg fentanyl (as citrate).1
Excipient(s): Each Actiq® lozenge contains dextrates (equivalent to approximately 2g of glucose), sucrose (approximately 30mg confectioner’s sugar) and propylene glycol (part of the artificial berry flavour and imprinting ink) as excipients.1
For a full list of excipients, see Section 6.1. of the Summary of Product Characteristics.1
Teva Pharma B.V.
2031 GA Haarlem
Marketing Authorisation Number(s)
1 Actiq® (Fentanyl citrate) - Summary of Product Characteristics
To access this section of the Teva UK Limited website you need to be a member of the healthcare profession
because the materials included in this area of our website are specifically prepared for that audience
To understand why that is - please visit: Working in a regulated environment
Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.